



Intraocular Biopsy and ImmunoMolecular Pathology
for “Unmasking” Intraocular Inflammatory Diseases
Rodolfo Mastropasqua 1,*, Emma Di Carlo 2,3, Carlo Sorrentino 4,5, Cesare Mariotti 6 and
Lyndon da Cruz 7,8,9
1 Eye Clinic, Polytechnic University of Marche, 60126 Ancona, Italy
2 Anatomic Pathology and Immuno-Oncology Unit, Center for Advanced Studies and Technology (CAST),
Via L. Polacchi 11, 66100 Chieti, Italy; edicarlo@unich.it
3 Department of Medicine and Sciences of Aging, “G. d’Annunzio” University of Chieti-Pescara,
66100 Chieti, Italy
4 Anatomic Pathology and Immuno-Oncology Unit, Center for Advanced Studies and Technology (CAST),
Via L. Polacchi 11, 66100 Chieti, Italy; carlo.sorrentino@unich.it
5 Department of Medicine and Sciences of Aging, “G. d’Annunzio” University of Chieti-Pescara,
66100 Chieti, Italy
6 Eye Clinic, Polytechnic University of Marche, 60126 Ancona, Italy; mariottic@libero.it
7 Vitreoretinal Department, Moorfields Eye Hospital, 162 City Rd, Old Street, London EC1V 2PD, UK;
lyndon.dacruz1@nhs.net
8 NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital, London, EC1V 2PD, UK
9 Institute of Ophthalmology, University College London, London EC1V 2PD, UK
* Correspondence: rodolfo.mastropasqua@gmail.com
Received: 12 August 2019; Accepted: 15 October 2019; Published: 19 October 2019


Abstract: Intraocular inflammation can hide a variety of eye pathologies. In 33% of cases, to obtain a
correct diagnosis, investigation of the intraocular sample is necessary. The combined analyses of the
intraocular biopsy, using immuno-pathology and molecular biology, point to resolve the diagnostic
dilemmas in those cases where history, clinical tests, and ophthalmic and systemic examinations
are inconclusive. In such situations, the teamwork between the ophthalmologist and the molecular
pathologist is critically important to discriminate between autoimmune diseases, infections, and
intraocular tumors, including lymphoma and metastases, especially in those clinical settings known
as masquerade syndromes. This comprehensive review focuses on the diagnostic use of intraocular
biopsy and highlights its potential to enhance research in the field. It describes the different surgical
techniques of obtaining the biopsy, risks, and complication rates. The review is organized according
to the anatomical site of the sample: I. anterior chamber containing aqueous humor, II. iris and ciliary
body, III. vitreous, and IV. choroid and retina. We have excluded the literature concerning biopsy for
choroidal melanoma and retinoblastoma, as this is a specialized area more relevant to ocular oncology.
Keywords: intraocular inflammation; intraocular biopsy; masquerade syndrome; intraocular
lymphoma; endophthalmitis; molecular pathology; immunohistochemistry; laser capture
microdissection; qPCR
1. Introduction
The diagnostic approach to intraocular infectious or inflammatory diseases is based on clinical
history and examination supported by serologic, microbiologic, and fundamental imaging tests.
The tests include ocular echography, fluorescein, and indocyanine green (ICG) angiography as well
as more advanced imaging technologies. These range from computed tomography (CT), magnetic
resonance imaging (MRI), and positron emission tomography (PET) to the recently introduced
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enhanced-depth imaging optical coherence tomography (EDI-OCT) and optical coherence tomography
angiography (OCTA).
Despite the diagnostic potential of these imaging techniques, investigating the intraocular biopsy
becomes essential in cases of atypical or aggressive clinical manifestations, difficulty identifying the
etiology, and excluding malignancy or failure of conventional therapy because of a misdiagnosis.
Currently, up to 33% of patients suffering from intraocular inflammation have undergone a biopsy [1].
The combined immunopathological and molecular diagnostics of the intraocular biopsy
discriminate between infectious and non-infectious, autoimmune or neoplastic causes by using
cutting-edge methods, such as laser capture microdissection (LCM) followed by polymerase
chain reaction (PCR), or multiplex PCR, real-time PCR, or metagenomic deep sequencing
(MDS). These procedures overcome the diagnostic limits of the traditional cytology, histology,
immunohistochemistry, and flow cytometry and are suitable for specimens with few or poorly
preserved cells.
The teamwork between the ophthalmic surgeon and the molecular pathologist, including planning
testing of the biopsy sample, leads to a correct diagnosis and early therapy of ocular pathologies and is
fundamental for discovering new molecular pathways and targets for tailored therapies.
Here, we provide a comprehensive overview of the diagnostic use of intraocular biopsy and
highlight its potential to enhance research in the field. The surgical techniques of sampling and the
usefulness of the intraocular biopsy will be discussed according to the anatomical sites as follows:
I. anterior chamber containing aqueous humor, II. iris and ciliary body, III. vitreous, and IV. choroid
and retina. The aqueous humor sampling does not involve the collection of tissue; therefore, it should
not be considered a biopsy. Since in some clinical pictures the anterior chamber sampling can be
diagnostic, the authors decided to describe it in this review for completeness.
2. Aqueous Humor Sampling
Anterior chamber (AC) paracentesis may have both therapeutic and diagnostic purposes.
As a therapeutic tool, it is useful in rapidly reducing intraocular pressure (IOP) in settings such
as scleral buckling, acute angle closure glaucoma, central retinal artery occlusion, and following
intravitreal injections [1–3]. As a diagnostic technique used for determining the etiology of anterior
uveitis, an AC paracentesis of approximately 100–200 µL is sufficient for both smear cytology and
immunocytochemistry (to promptly identify neoplastic and inflammatory cells) as well as leaving a
residual volume for further analysis, as suggested by clinical data and imaging tests [4–6]. Anterior
uveitis (AU) implies the presence of inflammatory cells in the AC (iritis) or the AC and anterior vitreous
(iridocyclitis) [7] and is found in 75% of all cases of uveitis. Clinically, using slit-lamp biomicroscopy the
finding of aqueous cells is diagnostic of iritis, which is often accompanied by aqueous flare composed
of albumin [8].
Anterior uveitis may occur due to a variety of causes, which entail substantial differences in the
therapeutic choice, and specifically, (i) infectious agents, such as Bartonella, Borrelia Brucella, Herpes
simplex 1 and 2 (HSV-1-2), Varicella zoster virus (VZV), Epstein–Barr virus (EBV), Cytomegalovirus
(CMV), Toxoplasma gondii (Toxo), Leptospira, Treponema pallidum, Mycobacterium tuberculosis
(TB); (ii) Immune-mediated and inflammatory (non-infectious) causes, that may be associated with
systemic diseases, such as sarcoidosis, ankylosing spondylitis (HLA-B27-associated uveitis), juvenile
rheumatoid arthritis, systemic lupus erythematosus, polyarteritis nodosa, Behçet disease, psoriasis,
Vogt–Koyanagi–Harada disease, multiple sclerosis or inflammatory bowel diseases; (iii) neoplastic
(masquerade category) and drug-induced causes related to different medications (including but not
limited to rifabutin, cidofovir, zoledronate and pamidronate) and, finally, (iv) traumatic causes [9].
A large proportion of AU is non-infectious and associated with the HLA-B27 haplotype; while
viral infections most commonly with those belonging to the Herpesviridae family; are regarded as an
important cause of infectious AU [10].
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Depending on the clinical picture the diagnostic aqueous humor (AH) tap may be analyzed
by: (i) western blotting (WB), to detect local antibody (Ab) production to a specific microbial
pathogen; (ii) determining the Goldmann-Witmer coefficient (GWC), to quantify Ab production,
(iii) enzyme-linked immunosorbent assay (ELISA) and/or by immunofluorescence assay, to detect
pro- and anti-inflammatory mediators; (iv) polymerase chain reaction (PCR), to amplify and detect
the DNA or RNA of specific viruses, bacteria, fungi, and parasites as well as detecting cytokine
and inflammatory related transcripts and, in cases requiring differentiation from lymphomas, for
assessing IgH or T-cell receptor (TCR) gene rearrangements (to identify B-cell and T-cell lymphomas,
respectively) [11,12]; (v) proteome analyses with a mass spectrometer (MS) coupled to a nano-LC-2D
HPLC system (ThermoFisher, Waltam Massachusetts, USA), to characterize the protein composition
of AH [13]. Although further analysis and validation are required to determine its reproducibility,
sensitivity, and specificity, proteomic analysis of AH is a promising strategy for diagnosing and treating
a wide range of diseases of the anterior segment [13,14].
Aqueous humor sampling is especially valuable diagnostically in patients with masquerade
syndromes, in the presence of a hypopyon (Figure 1), a typical sign of active acute AU. The hypopyon
consists of a collection of inflammatory cells, mostly granulocytes and possibly malignant lymphoid
cells, in the lower angle of the AC. A herpetic etiology can be suspected in patients with iris atrophy,
pigmented keratic precipitates, endotheliitis, or ocular hypertension [15,16]. Herpetic infections
usually manifest as non-granulomatous uveitis in acute cases and as granulomatous uveitis in chronic
cases [17,18]. Detection of the pathogens responsible for infectious uveitis, besides cytopathological
examination and microbiological tests, currently relies on PCR analyses of the AH sample, which is
easier to obtain than vitreous. By using a minimum volume of 0.05 mL of AH through PCR, specific
DNA sequences can be amplified to provide fast identification of specific pathogens [18,19]. The GWC
provides additional data to determine the pathogenic level of the virus load [10]. Combining PCR,
GWC, and WB has significantly increased the diagnostic sensitivity of PCR by up to 97% [20].
Figure 1. Hypopyon in a patient with infective uveitis. An anterior segment photograph of an eye of a
70-year-old male with hypopyon secondary to bacterial endophthalmitis.
Alternatively, real-time PCR, also called quantitative PCR (qPCR), provides both evidence and
quantification of the load of the pathogen, and thus allows distinguishing active infection from
low-grade pathogenicity. Currently, multiplex PCR allows for the amplification and detection of several
different sequences at the same time. Specific genomic DNA from different viruses, bacteria, and fungi
can be measured simultaneously in a small sample volume. At present, the combination of multiplex
PCR and qPCR, known as a comprehensive PCR system, has further improved the diagnostics of
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infectious uveitis, since it combines the possibility of detecting a variety of genomic DNA (HSVs, VZV,
EBV, CMV, Toxo, Parvovirus B19, BK virus, JC virus) with their subsequent quantitation. When the
multiplex PCR generates positive results, then qPCR is performed to quantify the copy number of the
genome in the sample and to confirm its pathogenic role [21].
Typically, AC and vitreous biopsies are performed together. In cases of acute malignant
lympho-proliferative process outpacing the clearance mechanism of AC, the abundance of tumor
cells within the pseudohypopyon can provide sufficient material for both cytopathology and flow
cytometry (which allows for the simultaneous analysis of several different leukocyte cell surface
markers) [22,23]. However, if a neoplastic pseudouveitis is suspected, the diagnostic value of AC
paracentesis is limited, since malignancies or metastases primarily involve the vitreous, uvea, or
retina [22,24] and the involvement of AC can be late or consisting of an inflammatory reaction, therefore
vitreous or chorioretinal (CR) biopsies are preferred.
2.1. Research in the Field
Analyses of cytokines, chemokines, or metalloproteinases in the AH are currently being developed
for diagnostic and prognostic purposes, in particular to meet the following needs: (a) differential
diagnosis between primary vitreoretinal lymphoma (PVRL) and uveitis. Interleukin-6 (IL-6) is
produced at high levels by inflammatory cells in uveitis, whereas IL-10 is produced by malignant
B lymphocytes in intraocular and central nervous system (CNS) lymphoma [25]. PVRL is typically
associated with an increased IL-10 to IL-6 ratio (greater than 1.0) [25–27]; (b) assessment of the
risk for developing secondary glaucoma in patients with juvenile idiopathic arthritis, who have
developed chronic anterior uveitis (JIAU). Increased level of TGFβ-2 in AH of these subjects has
been associated with intraocular pressure elevation and occurrence of secondary glaucoma [28];
(c) monitoring the response to anti-vascular endothelial growth factor (VEGF) drug treatment for
choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
Reduced levels of VEGF and pigment epithelium-derived factor (PEDF, also known as SERPINF1)
in AH are associated with response to treatment and disease inactivity [29–31]; (d) monitoring the
response to anti-VEGF drug treatment of diabetic retinopathy (DR) and diabetic macular edema
(DME). Increasing inflammatory cytokines concentrations are related to more severe stages of DR [32].
Levels of VEGF, IL-6, IL-8, inducible protein-10 (IP-10), intercellular adhesion molecule 1 (ICAM-1),
and monocyte chemotactic protein 1 (MCP-1) are associated with macular edema in type 2 diabetic
patients [33,34]. Decreased levels of pro-angiogenic and inflammatory mediators such as IL-6, IP-10,
MCP-1, PDGF-AA, and VEGF are related to a better therapeutic response and reduced impairment
of foveal thickness in DME [35]; (e) monitoring the response to immunosuppressive or biological
(anti-TNF-α) agents of autoimmune uveitis. The decrease in the AH levels of VEGF and IL-2 have
been associated with reduced intraocular inflammation [36]; and finally, (f) the development of tailored
treatment of non-infectious uveitis by targeting cytokines and their receptors. Assessment of the
cytokine profile by bead-based multi-detection assays may identify molecular mediators of uveitis and
provide new targets for therapy [37].
2.2. Surgical Technique
Several methods of AC paracentesis have been described [38,39]. Presently, AC paracentesis is
usually performed using a fine gauge needle from 27 to 30 gauge (G) attached to a 1 mL syringe.
AC paracentesis can be performed either under the operating microscope or at the slit lamp. Both
techniques are usually carried out under topical anesthesia and aseptic conditions. At the end of the
procedure, topical iodine or antibiotics should be instilled. The bevel of the needle should corneal
facing to avoid iris tissue incarceration [38,39]. The use of an operating microscope allows optimal
visualization of the AC during the procedure while the supine position and the surgical headrest
minimize head movements. It is also possible that lens touch is reduced with the patient supine
because of a slightly more posterior lens position. The use of a corneal pre-incision (partial thickness
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corneal incision) reduces the risk of touching the anterior capsule of the lens due to a more controlled
puncture of the AC [40]. However, the advantages of an operating microscope are not significant
enough to delay the AC tap especially in the presence of possible bacterial endophthalmitis.
Anterior chamber paracentesis is a safe technique with a low incidence of perioperative and
postoperative complications [38,41]. The complications related to this procedure comprise trauma to the
cornea, iris or lens, entry site leak, hypotony, hyphema, corneal abscess, or endophthalmitis [19,38,41].
The occurrence of hyphema was reported to be more frequent in eyes with elevated IOP [39]. In the
case of higher intraocular pressure (>30 mmHg), the procedure should be preceded by the reduction of
the IOP medically if possible. Some authors have advocated paracentesis in the presence of miosis to
reduce lens and iris complications. However, the complication rate is already low and comparable to
that reported in miosis [38,41].
Recently, Kitazawa et al. described a new technique for AC paracentesis, using a short 30 G needle
combined with a disposable pipette with a squeeze bulb located at its head, which allows the aqueous
humor sample to be drawn from the patient using one hand. The main advantage of this tool is to
produce no dead space, allowing for the aqueous humor to be obtained efficiently, even in cases with a
shallow AC. The authors reported no major complications in a series of 301 patients [42].
3. Iris and Ciliary Body Biopsy
Biopsies of the iris and ciliary body are primarily performed in cases of suspected neoplasia. Tumors
of these structures include malignant melanoma, more rarely medulloepitheliomas, and many benign
lesions, such as glioneuroma, hemangioma, leiomyomas, osteoma, and juvenile xanthogranuloma [43].
Since ophthalmic oncology goes beyond the objectives of this article, we will focus on those conditions
where iris and ciliary body biopsies can help in the diagnosis of intraocular inflammation of uncertain
origin. In particular, it can be useful in the investigation and management of infectious, autoimmune,
and idiopathic uveitis by means of histopathology and molecular analyses. Histopathological
examination of tissue can identify inflammation as acute or chronic, which is distinguished in
granulomatous and nongranulomatous.
Acute inflammation is often infectious in origin and timely diagnosis and treatment are
fundamental to optimize visual outcome. The causative organism, a bacterium (usually Gram-positive)
or fungus, may complicate the ocular surgery (most frequently cataract surgery, followed by intravitreal
injections, penetrating keratoplasty, trabeculectomy, and glaucoma drainage device implantation) or
be introduced through a perforating wound (exogenous endophthalmitis). Bacillus and Streptococcus
are common species found in penetrating trauma with an intraocular foreign body [44]. Other
species isolated include Staphylococcus epidermidis, Propionibacterium acnes, Pseudomonas and
Streptococcus, Gram−negative organisms, fungi, and mixed pathogens. Occasionally, the causative
microorganism reaches ocular tissues through the bloodstream (endogenous endophthalmitis) and may
be bacteria, mostly Streptococcus and Staphylococcus aureus in the majority of the population [45], and
Klebsiella pneumoniae in East Asian people [46] as well as fungi, particularly Candida albicans and
Aspergillus, and rarely parasites. The most common predisposing factors include immunosuppressive
diseases, such as diabetes mellitus, HIV infection, long-term use of broad-spectrum antibiotics,
steroids and other immunosuppressive drugs, indwelling intravenous catheters, and intravenous
drug abuse [47,48]. Acute endophthalmitis manifests as a massive purulent reaction in the anterior
and vitreous chambers, histologically represented by a massive granulocyte infiltrate, which can
disarrange the fibro-muscular structure of the ciliary body, as illustrated in Figure 2. A common cause
of noninfectious endophthalmitis is massive necrosis of a malignant uveal melanoma or a metastatic
carcinoma [49].
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Figure 2. Ciliary body biopsy from a 90-years-old male with acute suppurative endophthalmitis.
Hematoxylin and eosin (H&E) staining shows a massive influx of polymorphonuclear neutrophils
that fragments the fibro-muscular tissue of the ciliary body and also displaces and compresses the
pigmented (arrowheads) and non-pigmented (arrows) layers of the ciliary epithelium. Magnification:
×400; scale bar: 30 µm.
Chronic non-granulomatous inflammation of the eye histologically manifests as
lympho-mononuclear infiltrates that primarily involve the uveal tract. In most cases the chronic
inflammatory reaction has a viral etiology (primarily HSV and VZV) that can be determined by
molecular tests. Figure 3 shows a lymphocytic infiltration of the iris and ciliary body (Figure 3A) and
PCR detection of VZV DNA in the same tissues (Figure 3B).
Granulomatous inflammation may be the result of a specific infection such as toxoplasmosis
(Toxo), tuberculosis (TB), syphilis, nematodiasis, cytomegalic inclusion, or immune system disorders
such as sarcoidosis and collagen diseases [50,51]. In cases of uveitis where the etiology cannot be
ascertained, the entity will be designated as idiopathic granulomatous inflammation of the uveal tract.
Often, the most diagnostic lesions are not found in the iris, ciliary body, or choroid but rather in the
retina, vitreous, or sclera [52].
Iris biopsy, usually combined with AC tap is required to analyze iris stromal or epithelial cysts,
arising from posterior iris pigment epithelium or at the pupillary margin, associated with inflammation
and/or obstructing the visual axis [43,53,54]. In such cases, histopathology is essential in the differential
diagnosis between chronic granulomatous inflammations, juvenile xanthogranuloma, or malignant
lesions [43,50].
Iris and ciliary body biopsy may also be diagnostic in masquerade syndromes, when lymphoma,
the most common malignant orbital tumor, or metastasis, “hidden” by a reactive inflammation, are
suspected [55–57]. Iris and ciliary body can be infiltrated by metastatic adenocarcinoma (from the
breast, lung, or gastro-intestinal tract), systemic lymphoma, or by PVRL, which is rarely found here as
the first site of presentation [43,52,55–57]. The involvement of the anterior segment manifests with
abnormal iris vessels or nodules, hyphema, iridocyclitis, secondary glaucoma (including open angle,
closed angle, or neovascular), or clinically visible iris/ciliary body lymphoid infiltration [56,58–60] and
can precede detection of subretinal infiltrates [52,61].
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Figure 3. Ciliary body biopsy from a 66-year-old female with chronic non-granulomatous
endophthalmitis. (A) H&E staining reveals lymphoplasma cellular infiltrates and micro-hemorrhagic
events in the fibro-muscular structure of the ciliary body, close to the ciliary epithelium.
Magnification: ×400; scale bar: 30 µm. (B) Polymerase chain reaction (PCR) analysis
performed to detect Herpes simplex type 1 (HSV-1) and varicella zoster virus (VZV) DNA
(using the following primers, HSV-1-for, 5′-CTG-CAG-ATA-CCG-CAC-CGTATT-3′; HSV-1-rev,
5′-CAT-CTT-CGA-CCG-CCA-TCCCAT-3′; VZV-for, 5′-TCC-ATC-TGT-CTT-TGT-CTTTCA-C-3′;
VZV-rev, 5′-ATT-TTC-TGG-CTC-TAATCC-AAG-G-3) reveal positivity only for VZV DNA.
PVRL commonly affects elderly patients and manifests as a chronic uveitic masquerade syndrome
that is unresponsive to corticosteroid therapy. Histologically, the majority of primary anterior uveal
lymphomas are extra-nodal B-cell lymphoma of the marginal zone of mucosa-associated lymphoid
tissue (MALT lymphoma) [56,62] as shown in Figure 4. Intraocular T-cell lymphomas are uncommon,
and mostly represent metastasis of systemic T-cell lymphomas, including primary cutaneous peripheral
T-cell lymphoma, NK-T cell lymphoma, and rarely, adult T-cell leukemia/lymphoma (ATL) [63,64],
which penetrates the iris, ciliary body, and peripheral choroid.
Secondary intraocular lymphomas (SIOL) usually consists of a systemic diffuse large B cell
lymphoma [59] metastasizing to the iris, ciliary body, and choroid. In comparison with PVRL, SIOL are
much less prevalent; they typically manifest as a sudden and severe bilateral inflammatory reaction of
the anterior segment and are less likely to create a diagnostic dilemma.
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Figure 4. Ciliary body biopsy from an 82-year-old female with intraocular lymphoma. Extra-nodal
marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) is represented by small
lymphocytes with centrocyte-like features. Immunohistochemistry identifies the B cell phenotype
(CD20+) and also reveals the lack of bcl-6 expression and low proliferative activity (Ki-67, 5%).
Magnification: ×400; scale bars: 30 µm.
3.1. Research in the Field
In the last few years, in vitro and in vivo studies on the pathogenesis of ocular inflammation have
revealed that receptors expressed by the iris pigment epithelium (IPE) contribute to the development
of uveitis due to their ability to boost innate immune mechanisms through several inflammatory
mediators produced in response to ocular pathogens. Both IPE and retinal pigment epithelium (RPE)
form an interface between the eye and the environment that is not readily accessible to myeloid
cells [65–67].
By their ability to detect signals via innate immune receptors, such as Toll-like receptors (TLRs),
they can recruit myeloid cells, such as neutrophils and macrophages, to the site of injury and promote
inflammation. In particular, the lipopolysaccharide (LPS) receptor complex, which consists of two
interacting receptors (CD14 and TLR4) and an associated protein (MD-2) [68–70], when stimulated
by LPS, induces the production of pro-inflammatory cytokines by IPE [71–73]; especially IL-8, a
powerful neutrophil chemoattractant, and monocyte chemoattractant protein-1 (MCP-1/CCL2) that
regulates migration and infiltration of monocytes/macrophages. Unraveling the molecular drivers
of inflammation in the iris and ciliary body samples by immuno-pathological methods, PCR, WB,
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multiplex bead array, or biochip array technology, may in the future suggest appropriate targets for
personalized treatments of uveitis.
3.2. Surgical Technique
Iris and ciliary body specimens are typically accessible through a corneal or limbal incision mainly
with a fine needle aspiration biopsy (FNAB) [68–71]. This technique is performed under local anesthesia
using the operating microscope although biopsies taken at slit lamp are described. A 22–27 G needle
attached to a 10 mL syringe is required. Many authors have recommended the use of a connector
between the needle and the syringe to prevent the transmission of the surgeon’s hand movements to
the needle tip during aspiration [43]. Most frequently, the corneal access is either temporal or inferior,
as this allows a safe planar approach to the biopsy site without interference from the eyebrow and nose.
Filling the AC with a viscoelastic substance may limit possible complications. Once in the AC, the
needle, with the bevel side up, is passed through the aqueous into the biopsy site. The needle should
be parallel to the iris and directed in a straight line in order to avoid the pupillary margin and central
visual axis. The aspiration is usually maintained over 5 s ensuring that the needle is inside the biopsy
site and not merely aspirating aqueous. When the biopsy is completed, the needle has to be slowly and
carefully withdrawn and the viscoelastic substance removed. Balanced salt solution (BSS) is usually
used to reform the AC and normalize the intraocular pressure. In most cases, this technique does not
require corneal sutures. The limit of the FNAB is related to the relatively small sample achievable and
thus other transcorneal mini-invasive techniques have been described [69,71,72]. Surgical iridectomy,
with or without the use of a vitrectomy cutter, has also been described as an alternative technique.
Despite the larger specimen obtained, this is a more invasive procedure that often requires corneal
wound sutures, with subsequent visual rehabilitation [69,73–75]. The iris tissue obtained, regardless
of technique, is extremely fragile and should be handled with care and quickly transferred to the
laboratory in an appropriate preservative.
Potential intraoperative complications are the damage of the lens and the laceration of iris blood
vessels and the ciliary body causing hyphema. The occurrence of major postoperative complications
related is relatively rare [76]. These comprise persistent or recurrent hyphema, prolonged hypotony,
transient ocular hypertension after the AC refill, vitreous hemorrhage, and endophthalmitis [43,69].
4. Vitreous Biopsy
The vitreous plays a crucial role in the pathogenesis of many ocular inflammatory diseases and it
is also the compartment where cells and inflammatory mediators are released coming from pathologic
processes involving the choroid, retina, optic nerve, or ciliary body [77]. Vitreous sampling can be
obtained by pars plana (three-port) vitrectomy (PPV) or FNAB [26,60,78,79]. It is usually performed as
the primary procedure, when an invasive investigation is necessary because (a) it is more likely to lead
to a diagnosis than the AC paracentesis [80] and (b) it has a lower risk of complications than the CR
biopsy [81]. In clinical practice, the primary use of vitreous biopsy has been to identify the causes of
exogenous or endogenous endophthalmitis [82–85].
Specific indications for vitreous biopsy include: (1) providing a diagnosis in patients with
posterior uveitis when the etiology remains uncertain after clinical examination and ancillary tests.
An example is a PVRL, which manifests as persistent uveitis and requires pathological confirmation
to start the treatment [86]; (2) investigating failure of conventional therapy, which may be due to a
misdiagnosis, resulting in intractable disease; (3) diagnosing a sight-threatening disease that necessitates
an invasive approach for diagnosis and, at times, also for treatment, such as in the cases of infectious
endophthalmitis [87] and acute retinal necrosis (ARN) [88].
To reach the correct diagnosis in the cases of inflammatory, infectious, or neoplastic diseases of
uncertain origin, the vitreous biopsy can be examined by a variety of laboratory tests, such as culture
and microbiological tests, histopathology (for PPV) or cytology and immunocytochemistry (for FNAB),
PCR methods, flow cytometry, Ab measurement (by GWC), and cytokine evaluation (by ELISA) [86].
J. Clin. Med. 2019, 8, 1733 10 of 23
The sample is processed based on clinical features and the suspected disease, taking care to proceed
rapidly to avoid necrosis of the few inflammatory or neoplastic cells recovered.
The biopsy specimen should be divided into three samples: the first to be fixed for routine
histopathological evaluation; the second to be frozen in optimal cutting temperature (OCT), the
embedding compound for immunopathological and molecular characterization; and the third
intended for the culture of bacteria and other microorganisms. If the biopsy specimen is not
sufficient for all of these processes, it should be processed for frozen sections to allow histopathology,
immunohistochemistry, and molecular analysis.
Histologic or cytologic examinations of vitreous samples are generally the first step in the
pathologic diagnosis of PVRL, which in this site usually arranges as neoplastic sheets [26,52,60,89–94].
Recently, it has been demonstrated that cell block preparation is more useful for diagnosis of vitreoretinal
lymphoma than conventional smear cytology [95]. This method, which employs the retrieval of small
tissue fragments from a cytologic specimen that are processed to form a paraffin block, increases
cellular yield and obtains numerous tissue sections for multiple immunostainings [96].
Flow cytometry and immunohistochemistry allow the identification of lymphoma cells and
demonstrate their monoclonality by B-cell and plasma cell markers (CD19, CD20, CD22, BCL-6, MUM1)
and kappa or lambda light chain restriction [94].
Assessment of cytokine production, specifically IL-6 and IL-10, discriminates between PVRL and
other ocular inflammatory processes. As in the AH, an association of PVRL with an increased IL-10 to
IL-6 ratio has also been found in the vitreous [25–27,97].
Molecular analysis of a vitreous specimen using PCR techniques has two main indications: (1) to
diagnose PVRL and (2) to detect and identify the DNA of specific microorganisms in cases of infectious
uveitis [98]. For PVRL diagnosis, PCR is used to detect monoclonality within the variable region
of the third complementary determining region (CDR3) in the immunoglobulin heavy chain gene
of malignant B cells. PCR and microdissection have also been used for the detection of the t(14:18)
translocation (i.e., translocation between the genes for BCL-2 and IgH) [99,100].
The ageing population and the increase in patients with immunodeficiency (including HIV
infection) or immunosuppression have dramatically increased the incidence of vitreoretinal lymphoma
(VRL). The disease is inevitably accompanied by an inflammatory reaction and often masquerades as
intraocular inflammation [101]. PVRL is a malignant non-Hodgkin’s lymphoma (NHL) which either
occurs independently to, or in association with, primary central nervous system lymphoma (PCNSL).
It involves the retina, the vitreous chamber and/or the optic nerve (vitreoretinal form) and has to
be distinguished from secondary intraocular lymphoma (SIOL), an ocular manifestation of systemic
NHL, which predominantly infiltrates the uveal tract, particularly the choroid (uveal form) [60,102].
Most PVRL are diffuse large B-cell lymphomas (DLBCL), according to the updated World Health
Organization (WHO) lymphoma classification [103]; SIOL usually corresponds to the subtype of
systemic lymphoma [60]. Intraocular T-cell lymphomas are rare, and most cases occur secondary to
primary cutaneous or other systemic T-cell lymphomas.
In order to improve the diagnostic yield, PPV is the procedure of choice and may be both diagnostic
and therapeutic, particularly in patients with significant vitreous opacity [86,104]. Mudhar and Sheard
underlined that a full PPV may be preferred to a core vitrectomy to reduce the rate of false negative
results [105]. They claim that inflammatory and lymphoma cells, mostly located in the cortical vitreous,
have less chance to be sampled if a single core vitreous biopsy is performed.
In terms of a demonstration of the combination therapeutic and diagnostic effect of vitrectomy, the
randomized multicenter clinical trial known as “The Endophthalmitis Vitrectomy Study (EVS)”, has
demonstrated that immediate PPV is of substantial benefit for the treatment of postoperative bacterial
endophthalmitis in patients with visual acuity of light perception (LP) [85]. It gives a chance of visual
improvement due to the removal of the vitreal opacity and provides a very large volume sample for
diagnostic purposes.
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4.1. Research in the Field
As the vitreous contains proteins, proteoglycans and small molecules that originate from within
and outside the eyes, and that change qualitatively and quantitatively following vitreoretinal
diseases, the vitreous proteome is being studied to determine the molecular mechanisms of
these pathologies. The advent of mass spectrometry (MS)-based proteomic technologies (i.e.,
matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry and
liquid chromatography-tandem mass spectrometry (LC-MS/MS)) have facilitated de novo identification
and quantification of a large number of proteins within a relatively small sample. In particular, the
proteomic analysis of vitreous has provided novel insights into the etiology of diabetic retinopathy
and candidate targets for treatments, while it looks promising to identify factors predicting risk and
functional outcomes of interventional therapies [106,107].
4.2. Surgical Technique
Vitreous biopsy can be obtained under local anesthesia, by mean of FNAB (topical or
subconjunctival infiltration) or PPV [108]. In the FNAB technique, a short 27 or 25 G needle on
a syringe is inserted 3.5 to 4 mm away from the limbus (depending on lens status) and vitreous fluid
is aspirated. If the first aspiration does not yield fluid, the needle can be withdrawn slightly, and
aspiration may be attempted again. It is important to avoid the crystalline lens, as well as the retina
when entering the eye with the needle. This technique is considered relatively safe [109] although
major complications such as hemorrhage, retinal detachment, proliferative vitreous retinopathy, and
endophthalmitis have been described [78,109,110].
Biopsies with PPV have been routinely described with 20, 23, or 25 G equipment with a move to 27
G being reported more recently [111]. The procedure can be limited to a diagnostic core vitrectomy or
can be extended to a full vitrectomy with an induced posterior vitreous separation (PVD) that provides
the opportunity to achieve both a diluted and an undiluted sample. In most cases, an infusion port is
placed but not turned on before the ‘neat’ biopsy has been completed to avoid diluting the sample.
One or two further sclerotomies are placed in the superonasal and superotemporal quadrants. A
two-port sample can be taken if only a core sample is desired and the search for retinal tears can be
carried out with the indirect ophthalmoscope. The neat sample is taken with manual aspiration into a
syringe through the broken aspiration line while the vitrectomy cutter is activated (Figure 5A). An
assistant applies gentle suction using the syringe to aspirate the neat core vitreous sample (Figure 5B).
It is possible to obtain 2 mL of vitreous this way, but it is more common to aspirate 0.5–1.0 mL
(Figure 5C). The surgeon maintains the IOP by external pressure on the globe with a squint hook (or
other instruments) to counter the loss of intraocular volume. The vitrectomy cutter is withdrawn while
still ‘cutting’ and the sclerotomies are closed as usual.
The advantage of a formal vitrectomy over a vitreous tap is the volume achieved and the large
undiluted specimen allows extensive laboratory analyses [105]. Any cytokine analysis or diagnostic
testing measuring specific concentrations (e.g., cytokine levels, qPCR testing) should be performed
using undiluted vitreous because a specimen diluted by infusion fluid renders the concentrations
inaccurate and falsely low. The diluted sample and vitreous cortical cells, contained in the vitrectomy
cassette, can be used for cytopathology, flow cytometry, or other laboratory tests, after being centrifuged
to concentrate the cells [86]. Since cells removed from the vitreous are liable to rapid degeneration
unless fixed or exposed to the tissue culture medium promptly [75,112], the vitreous specimen has to
be transported quickly for laboratory analysis. Although diagnostic vitrectomy has been considered a
relatively safe procedure, the occurrence of complications such as intra and post-operative vitreous
hemorrhage and retinal detachment (most commonly) as well as choroidal effusion, proliferative
vitreoretinopathy, or endophthalmitis are frequently reported [84,113–115]. Extension of the lymphoma
through the sclerotomy port to the epibulbar space following vitrectomy has also been described as a
rare complication of a vitrectomy-based biopsy [116].
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Figure 5. Obtaining a vitreous sample with vitrectomy. (A) The assistant is manually aspirating via
a syringe while the surgeon is cutting with the vitrector. (B) The vitreous cutter shows the broken
aspiration tube (arrows) connected directly to a 2 mL syringe used to obtain a biopsy. (C) Undiluted
vitreous specimen obtained using the vitreous cutter.
5. Chorioretinal Biopsy
The limited number of publications on CR biopsies reflect the rarity of its use due to the complexity
of the surgical procedure, the risk of serious complications, and the fact that the diagnosis is frequently
reached with more straightforward and less invasive techniques. Indications for a CR biopsy primarily
includes the suspicion of malignancy, progressive sight-threatening retinal or choroidal lesions (retinitis
and choroiditis) unresponsive to therapy, sight-threatening involvement of the second eye despite
treatment, and negative vitreous analysis after multiple diagnostic biopsies and vitrectomies [117,118].
Mastropasqua et al. proposed the level of vitritis as an index of likelihood in achieving a definitive
diagnosis by means of a CR biopsy in masquerade syndromes [119].
When the sensory retina, RPE, or choroid are the only ocular tissues involved in the disease, the
choice of proceeding directly with a CR biopsy and avoiding a diagnostic vitrectomy, can prevent the
risks linked to multiple surgeries [120–122]. The surgical technique for performing a CR sampling can
either be FNAB, full-thickness CR biopsy or trans-scleral biopsy using a partial scleral thickness flap,
depending on the location of the lesion [81,108,123,124].
Obtaining CR specimens is effective in the diagnosis of infectious retinitis, such as herpes simplex
virus, caricella zoster virus, Cytomegalovirus, Candida albicans, Pneumocystis jirovecii (previously
known as Pneumocystis carinii), Toxoplasma gondii and Mycobacterial [81,118,125–129]. However,
a CR biopsy is not the primary diagnostic approach for these diseases, since analyses of intraocular
fluids (aqueous or vitreous to detect microbial DNA by PCR or to quantify specific Abs), blood,
or cerebrospinal fluid associated with imaging testing (optical coherence tomography (OCT) and
fluorescent or indocyanine green angiography) are usually performed first and sometimes prove
conclusive [130,131].
Handling of the CR biopsy depends on the amount of tissue harvested. To avoid necrosis, the
ocular tissue must be rapidly divided (in a sterile manner under a dissecting microscope) and included
in selected tissue culture for microbiology, fixed in formalin for histopathology, fixed in glutaraldehyde
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for electron microscopy (assessment of viral particles), or frozen for molecular biology. Consultation of
the molecular pathologist will be decisive in choosing the most appropriate test.
The analysis of CR samples is of paramount importance in the diagnosis/exclusion of malignancy,
particularly in lymphoma [60,75,81,119,121,132–136]. Primary vitreoretinal lymphoma (PVRL) is the
most common intraocular lymphoma [137]; usually, a high-grade diffuse large B-cell malignancy
manifests with choroidal infiltration, vitritis, or even necrotizing retinitis are unresponsive to anti-viral,
anti-bacterial, and anti-parasitic therapy. In PVRL, the main site of involvement is the sub-RPE space
(between RPE and Bruch membrane) [124] since lymphoma cells express specific ligands, leading to
preferential homing to the RPE (Figure 6); therefore, the diagnostic rate of CR biopsy is high. When
an internal approach is used specimens must be taken from the deeper part of the lesion, near the
choriocapillaris, where viable lymphoma cells are most likely to be found since sub-retinal tumors can
be largely necrotic [59,124].
Figure 6. Primary vitreoretinal lymphoma in a 68-year-old female. Pleomorphic lymphomatous cells
(blue arrow), lying between the retinal pigment epithelium (RPE) (black arrow) and the underlying
choroid. The choroid has a reactive infiltrate of small non-neoplastic lymphocytes (green arrow). H&E
staining used; magnification: ×400; scale bar: 30 µm (Department of Eye Pathology, UCL Institute of
Ophthalmology 2014).
In most cases, lymphoma cells are interspersed with reactive lymphocytes and necrotic cell
debris, thus reducing the purity of DNA for molecular analyses and making the results unreliable.
Laser capture microdissection (LCM) by isolating lymphoid cells from tissue sections, may increase
the sensitivity and specificity of PCR from an average of 60% to nearly 100% [11]. In the case
illustrated in Figure 7, atypical lymphoid cells were isolated by LCM, from a paraffin-embedded
intraocular tissue sample and, after DNA extraction, PCR was performed by using the specific primers
IgH-FR2A, IgH-FR3A, and IgH-CDR3 for immunoglobulin IgH rearrangements, and a specific primer
TCR-CDR3 for TCR rearrangements. The positivity for IgH-FR2A and IgH-CDR3 and the lack of TCR
rearrangements identify the B cell origin of the microdissected lymphoma cells.
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Figure 7. Laser capture microdissection (LCM) of lymphomatous B cells performed on a chorioretinal
biopsy from an 85-year-old female with intraocular lymphoma. (A) H&E staining shows few
lymphomatous cells confined close to the sclera by a significant chronic inflammatory reaction.
(B) The lymphomatous cells were dissected and removed from the tissue section by LCM. Magnification:
×400; scale bar: 30 µm. (C) PCR analysis performed to assess the B or T cell origin of the lymphomatous
cells (using three primer pairs: CDR3, IgH-FR2A, and IgH-FR3A, specific for IgH gene rearrangements
and one primer pair, T-cell receptor (TCR)-CDR3, specific for TCR gene rearrangements) reveals
positivity for IgH-FR2A and IgH-CDR3 and the lack of TCR rearrangements, thus identifying the B cell
origin of the cancer cells.
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5.1. Research in the Field
The use of LCM followed by PCR, transcriptomic or proteomic analyses, has proven to be effective
for the diagnosis and/or molecular and genetic investigations of vitreous biopsy samples with few or
poorly preserved cells. Very promising is the application of untargeted metagenomic deep sequencing
(MDS) to the clinical diagnosis of infectious diseases. This revolutionary high-throughput sequencing
technology overcomes limitations of traditional methods based on targeted approaches to specified
infectious agents (leading to potential missed pathogens) or specific genetic aberration (leading to
overlook of less common cancer driver mutations). MDS allows for an unbiased and rapid method for
detection of all pathogens (fungi, parasites, DNA and RNA viruses) [138] in a small volume specimen
and simultaneously, provides genetic information (chromosomal translocations, common and rare
mutations, gene rearrangements) for the diagnosis of non-infectious intraocular diseases, such as
malignant lymphoproliferative disorders [139].
5.2. Surgical Technique
Chorioretinal biopsy has been described, both under general or local anesthesia, and through
both external (transscleral) or internal approaches (transvitreal or FNAB).
The transscleral approach was the first to be described but is currently rarely performed due to
the risk of suprachoroidal hemorrhage and other serious complications [140,141]. For lesions anterior
to the equator and especially those around the ora, however, an external approach is sometimes
more practical for access. The intraocular approach provides advantages of direct visualization of the
lesion and gives visualized control of intraocular bleeding with internal tamponade, and diathermy if
needed [86].
The external technique requires a conjunctival peritomy and the isolation of the rectus muscles.
The biopsy site is marked on the sclera, and a nearly full-thickness scleral flap (generally 6 × 6 mm)
is performed. Thereafter, the flap is retracted, and diathermy is applied to the outer margin of the
choroidal bed. A sharp blade is then used to incise the choroid, and the biopsy specimen is grasped
with forceps. Vannas scissors may then be used to excise the specimen. The biopsy specimen is placed
in fixative. The scleral flap is then sutured back into place with 7-O Vicryl sutures [118].
The transvitreal approach that was described by Freeman [142] and further developed in several
variations [117,118,128,133] is considered safer and more reproducible [119,125,133]. In this technique,
the biopsy site should be chosen preoperatively and should include the junction of the involved and
uninvolved retina, as the margins of the lesion have a higher probability of showing the pathologic
process [118] (Figure 8). Central areas may have only necrotic tissue present providing inconclusive
histology [142]. At the beginning of the procedure a neat vitreous sample is often obtained as
described before. A complete standard PPV is then performed. In the biopsy area, retinal vessels
must be treated with endocautery to limit subsequent bleeding. The choroidal area to be cut is
then delineated with a diode laser or full-thickness diathermy. The retina and choroid are cut
through to bare sclera using vertical cutting segmentation-scissors. Soft-tipped cannula or forceps
are then used to remove the specimen through an enlarged sclerotomy, especially if the specimen
is particularly large. The biopsy site is encircled with endolaser followed by tamponade with
long-acting gas or silicone oil. Modern surgical techniques have dramatically decreased the incidence
of complications from all vitreoretinal procedures including CR biopsy, but it remains the most high-risk
intraocular biopsy technique available [133]. Reported complications of this surgery include cataract,
retinal detachment, vitreous hemorrhage, choroidal hemorrhage, proliferative vitreoretinopathy, and
endophthalmitis [73,81,117,119,123,128,133,143].
The FNAB for chorioretinal lesions is performed using a 25 to 30 G needle connected via a 12–18
in. segment of plastic tubing to a 10-mL aspirating syringe [68,118]. Connector tubing is used so
that there will be no induced movement of the needle as the assistant exerts suction in the line for
aspiration. The needle is inserted via the pars plana under direct visualization with either the operating
microscope or the indirect ophthalmoscope, and the tip of the needle is advanced until it is within
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the lesion. Aspiration is performed multiple times. Then the needle is carefully withdrawn from the
eye. Although the potential intra-operative risks are the same of the transvitreal procedure, the FNAB
technique seems to be less invasive and therefore, has and causes fewer complications relative to CR
biopsy performed by the internal approach [122,133,143].
Figure 8. Chorioretinal biopsy. (A) A fundus photograph of the left eye of a 68-year-old patient with
diffuse yellowish infiltrate suspected of having vitreoretinal lymphoma. (B) A fundus photograph
of the same eye filled with silicone oil, three months after a chorioretinal biopsy. The specimen was
diagnostic for “large B-cell lymphoma”. Note the biopsy site (arrows) and the regression of the tumor
after a cycle of chemotherapy (encircled by dotted line).
6. Conclusions
Intraocular biopsy is essential for a correct diagnosis in many cases of ocular inflammation.
A significant number of these conditions manifest a persistent and/or progressive disease, which can
result in severe visual impairment due to damage to the ocular structures. Timely and definitive
diagnosis and subsequent appropriate and specific therapy may be sight saving. As such, the most
common indication for intraocular biopsies is atypical uveitis, when a diagnosis of malignancy or
infection may be suspected, or chronic and non-resolving uveitis. Ocular lymphoma remains the
common malignancy that is diagnosed with ocular biopsy and in these situations, a definitive diagnosis
is central to reducing morbidity and mortality. Modern vitrectomy techniques with endoresection,
as well as more reliable vitreous and aqueous sampling, obtain appropriate tissue samples more
consistently, with a relatively low risk of complications. These biopsy techniques, together with
cutting-edge molecular tools, enable both the achievement a definitive diagnosis and the development
of tailored therapies for inflammatory eye diseases.
7. Method of Literature Search
PubMed and Medline advanced searches were undertaken. Only English language articles from
peer review journals were evaluated. A total of 372 articles were retrieved, of which 143 articles were
relevant and were included in this review.
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